1.	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 35 to 90 Sponsor: Other Protocol IDs: 047838, NCT00805701
2.	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: ANG-CP-003, NCT00953277
3.	Stereotactic Body Radiotherapy for Prostate Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-022, NCT01352598
4.	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Phase: Phase IV Type: Treatment Status: Active Age: 40 and over Sponsor: Other Protocol IDs: Thin-1, NCT01379742
5.	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IRB# 11-002288, NCT01365143
6.	Firmagon (Degarelix) Intermittent Therapy Phase: Phase IV Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: CURC - FIT-0002, NCT01512472
7.	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 4-2007-0344, NCT01547416
8.	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Phase: Phase IV Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: R12-3104L, NCT01581749
9.	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CABAZ_L_06003, U1111-1123-9025, NCT01649635
10.	GP Extended Action Triptorelin Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A-97-52014-181, 2011-004213-16, NCT01673984
11.	STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial Phase: Phase III, Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: CDR0000455008, MRC-STAMPEDE, EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476
12.	Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
13.	Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 40 to 75 Sponsor: NCI Protocol IDs: UIC-2006-0706, 2006-0706, NCT00765479
14.	External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: GU004-11, NCT01603420
15.	Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: RRK4368, 2012-002552-16, NCT01668459
16.	Hormone Therapy in Treating Men With Stage IV Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: Adult Sponsor: NCI Protocol IDs: SWOG-9346, SWOG-9346, CAN-NCIC-PR8, CALGB-9594, ECOG-S9346, EORTC-30985, CAN-NCIC-JPR8, INT-0162, NCT00002651, PR8
17.	Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer Phase: Phase III Type: Supportive care, Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: FCCC-03028, NCT00084552
18.	Androgen Deprivation Therapy in Treating Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: PMCC-VCOG-PR-0103, PMCC-TROG-0306, NCT00110162
19.	Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: Under 75 Sponsor: Other Protocol IDs: CDR0000416088, FRE-FNCLCC-GETUG-14/0207, EU-20503, NCT00104741
20.	Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 30 and over Sponsor: Other Protocol IDs: 05-043, NCT00116142
21.	Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy Phase: Phase III Type: Treatment Status: Active Age: 20 to 79 Sponsor: Other Protocol IDs: JCOG0401, C000000026, NCT00138008
22.	Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: PCS III, DC-990-0049, NCT00223145
23.	Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: PCS IV, DC-990-0056, NCT00223171
24.	Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: R03-1213, NCT00175383
25.	Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: R04-0050, NCT00175396